Medicus Pharma gains after cutting royalty payment to Teverelix

Medicus Pharma

22/01/2026 13:03

** Shares of drug developer Medicus Pharma MDCX.O rise 12% to $1.49 premarket

** Co says it has cut royalty payments on investigational prostate cancer drug teverelix to 2% from ~4% after amending its deal with UK research group LifeArc

** Co's teverelix is being tested for advanced prostate cancer and recurring acute urinary retention, a condition where men suddenly cannot urinate

** Co says early studies showed teverelix quickly lowers hormone levels key to prostate cancer treatment

** MDCX plans mid‑stage testing before seeking commercial partners; also expects early‑2026 data for its SkinJect skin cancer patch, per co

** Shares down ~37% in 2025

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))